Fresenius SE & Co. KGaA

Equities

FRE

DE0005785604

Healthcare Facilities & Services

Real-time Estimate Tradegate 06:46:53 2024-04-12 am EDT 5-day change 1st Jan Change
25.5 EUR +0.81% Intraday chart for Fresenius SE & Co. KGaA +1.67% -9.01%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cannabis law and clinic atlas in the Bundesrat DP
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
Criticism of hospital reform: 'Redistribution from the bottom to the top' DP
European Equities Traded in the US as American Depositary Receipts Flat in Tuesday Trading MT
Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar MT
Fresenius Settles With Johnson & Johnson to Market Stelara Alternative DJ
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Friday Trading MT
Doctors strike at university hospitals DP
Doctors go on warning strike at 23 university hospitals DP
FRESENIUS SE : Gets a Buy rating from Berenberg ZD
European Equities Traded in the US as American Depositary Receipts Advance Wednesday MT
ADRs Slump, Quoin Pharmaceuticals Ltd. Declines 48.3% DJ
Sector Update: Health Care Stocks Retreating Late Afternoon MT
Sector Update: Health Care Stocks Lower Tuesday Afternoon MT
Fresenius Medical Care to Sell Dialysis Clinics in Brazil, Colombia, Chile, Ecuador to DaVita MT
European Equities Traded in the US as American Depositary Receipts Decline Tuesday MT
FRESENIUS SE : Deutsche Bank remains its Buy rating ZD
European Equities Traded in the US as American Depositary Receipts Open Week Flat in Monday Trading MT
FRESENIUS SE : Receives a Buy rating from UBS ZD
FRESENIUS SE : Berenberg gives a Buy rating ZD
Berenberg: Fresenius Medical Care to Experience Solid Growth in FY24 as Demand Recovers MT
FRESENIUS SE : Barclays reaffirms its Buy rating ZD
Solution for transparency and financing at hospitals DP
FRESENIUS : A good ending does not allow for extreme optimism in 2024 Alphavalue
FRESENIUS SE : Deutsche Bank remains its Buy rating ZD
Chart Fresenius SE & Co. KGaA
More charts
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.; - hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
25.3 EUR
Average target price
36.22 EUR
Spread / Average Target
+43.16%
Consensus
  1. Stock Market
  2. Equities
  3. FRE Stock
  4. News Fresenius SE & Co. KGaA
  5. Germany's Fresenius Forecasts Revenue Growth in FY24